The estimated impact of human papillomavirus vaccine coverage on the lifetime cervical cancer burden among girls currently aged 12 years and younger in the United States

Sexually Transmitted Diseases

Volumn 41, Issue 11, 2014, Pages 656-659

  Chesson, Harrell W ^a   Ekwueme, Donatus U ^b   Saraiya, Mona ^b   Dunne, Eileen F ^a   Markowitz, Lauri E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER MORTALITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; INFANT; NEWBORN; SURVIVAL RATE; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; ADOLESCENT; ATTITUDE TO HEALTH; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; HEALTH CARE SURVEY; IMMUNOLOGY; MASS IMMUNIZATION; ORGANIZATION AND MANAGEMENT; PAPILLOMAVIRUS INFECTIONS; PATIENT ATTITUDE; PREVALENCE; PREVENTIVE HEALTH SERVICE; STATISTICAL MODEL; UTERINE CERVICAL NEOPLASMS;

ADOLESCENT; CHILD; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; IMMUNIZATION PROGRAMS; MASS VACCINATION; MODELS, ECONOMIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; PREVALENCE; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 84930024698     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000199     Document Type: Article

References (20)

1. U.S. Department of Health and Human Services. Office of Disease Prevention and Health Promotion. Healthy People 2020 2013. Washington, D.C.
2. Curtis CR, Yankey D, Jeyarajah J, et al. National and state vaccination coverage among adolescents aged 13-17 yearsVUnited States, 2012. MMWR 2013; 62:685-693.
3. Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011; 29: 8443-8450.
4. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010; 28:6858-6867.
5. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339:b3884.
6. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2003 Incidence and Mortality. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2006.
7. Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: A national resource. Cancer Epidemiol Bio-markers Prev 1999; 8:1117-1121.
8. National Cancer Institute. Surveillance Epidemiology and End Results. Bethesda, MD; 2013.
9. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359:821-832.
10. Insinga RP, Ye X, Singhal PK, et al. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan. Gynecol Oncol 2008; 111:188-196.
11. Chesson HW, Ekwueme DU, Saraiya M, et al. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine 2012; 30:6016-6019.
12. Van de Velde N, Boily MC, Drolet M, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavi-rus vaccines: A model-based analysis. J Natl Cancer Inst 2012; 104: 1712-1723.
13. Van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. Vaccine 2010; 28:5473-5484.
14. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103:1444-1451.
15. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: A systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781-789.
16. Luxembourg A. 9-Valent HPV (9vHPV) vaccine program key results [presentation]. 2014. Meeting of the Advisory Committee on Immunization Practices; Atlanta, Georgia; February 27, 2014.
17. Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genom 2009; 12:343-351.
18. Chesson HW, Ekwueme DU, Saraiya M, et al. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008; 14:244-251.
19. Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014. MMWR Morb Mortal Wkly Rep 2014; 63:620-624.
20. U.S. Census Bureau. Annual estimates of the resident population by single year of age and sex for the United States: April 1, 2010 to July 1, 2012. 2013. U.S. Census Bureau, Population Division.